Researchers at the Translational Genomics Research Institute (TGen), the Van Andel Research Institute (VARI) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.
Using a particular biomarker, researchers might better predict which patients with small cell lung cancer are resistant to existing drug therapies, and which ones could benefit from new therapies tailored to their specific needs, according to a scientific paper published today in the Journal of Thoracic Oncology.
"There is a need for predictive biomarkers that can aid investigators in designing future clinical trials, to help identify treatments that might be effective for these patients who most likely will be resistance to existing drug therapies, " said Dr. Glen J. Weiss, the paper's senior author and Director of Thoracic Oncology at TGen Clinical Research Services at Scottsdale Healthcare. TCRS is a partnership between TGen and Scottsdale Healthcare that helps bring new therapies quickly to patients at the Virginia G. Piper Cancer Center in Scottsdale.
Nearly 220,000 Americans are diagnosed each year with lung cancer, which is by far the leading cause of cancer death in the U.S., annually killing nearly 160,000 patients.
Of all lung cancer patients, an estimated 33,000 are diagnosed with SCLC. This is a particularly aggressive disease that usually goes undetected until it is in an advanced stage and treatment options are limited. More than 95 percent of SCLC patients eventually die from the disease.
Researchers from TGen, VARI and the Virginia G. Piper Cancer Center at Scottsdale Healthcare focused on identifying microRNAs, which are single-stranded RNA molecules that regulate how genes and proteins control cellular development. Because microRNAs are so resilient, they are relatively easy to detect in tumor tissue and blood, which is often a limitation for other biomarkers.
"VARI provided bioinformatics support assembling all the different types of data into a cohesive data set for analysis to help identify the miRNA that play a role in the survival of the lung cancer patients," said Dr. David Cherba, a VARI Bioinformatics Scientist.
Researchers profiled 34 tumor samples from patients with a median age of 69. They analyzed each tumor's microRNAs, searching for those that might be associated with cancer survival.
They identified three microRNAs associated with SCLC. But one in particular, identified as miR-92-2*, was "significantly" linked to survival, the paper said.
This microRNA could be used in two significant ways:
As a predictive biomarker in the development of new treatments for those SCLC tumors that prove to be de novo chemoresistant — possessing properties that render them inherently resistant to existing drug therapies.
As prognostic biomarkers in the screening of SCLC patients and the design of clinical trials better tailored to their prognosis.
"Our results demonstrate that higher tumor miR-92a-2* levels are associated with chemoresistance and with decreased survival in SCLC patients," said the paper titled MicroRNA 92a-2*, a Biomarker Predictive for Chemoresistance and Prognostic for Survival in Small Cell Lung Cancer Patients.
This was one of the first scientific papers published since the completion of the TGen-VARI alliance and affiliation agreement, announced in February.
"The collaboration that occurred on this project highlights the synergies created by the VARI-TGen alliance," said Dr. Craig Webb, a VARI Senior Scientific Investigator.
Dr. Jeffrey Trent, President and Research Director for TGen and VARI, said the new discoveries could have profound implications for the future of medicine.
"This advanced technology is exciting because of how these microRNA biomarkers could lead to improvements for patients. Hopefully, this will translate to new treatments and improved survival," Dr. Trent said.
The next step in this research should be to attain further validation by analyzing additional independent samples, the paper concludes.
This study was funded by the American Cancer Society, a Sylvia Chase Pilot Grant and the IBIS Foundation of Arizona.
About the Virginia G. Piper Cancer Center at Scottsdale Healthcare
The Virginia G. Piper Cancer Center at Scottsdale Healthcare offers diagnosis, treatment, research, prevention and support in its facilities at the Scottsdale Healthcare Shea Medical Center, attracting patients from across Arizona and the U.S. Groundbreaking cancer research is conducted through its Scottsdale Healthcare Research Institute in collaboration with TGen and leading universities. Scottsdale Healthcare is the not-for-profit parent organization of the Scottsdale Healthcare Shea Medical Center, Scottsdale Healthcare Osborn Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center, Scottsdale Healthcare Research Institute and Scottsdale Healthcare Foundation. For additional information, please visit www.shc.org.Press Contact:
Steve Yozwiak | EurekAlert!
Toward a 'smart' patch that automatically delivers insulin when needed
18.01.2017 | American Chemical Society
127 at one blow...
18.01.2017 | Stiftung Zoologisches Forschungsmuseum Alexander Koenig, Leibniz-Institut für Biodiversität der Tiere
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
18.01.2017 | Power and Electrical Engineering
18.01.2017 | Materials Sciences
18.01.2017 | Life Sciences